{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:43:43Z","timestamp":1787773423628,"version":"build-2784847793"},"reference-count":26,"publisher":"SLACK, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pediatr Ophthalmol Strabismus"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To ascertain the effectiveness of 0.01% atropine treatment to inhibit myopia progression and the possible additive potency with peripheral defocus contact lenses over 3 years and the rebound effect 1 year after cessation of treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This prospective study included 127 children aged 8 to 5 years, divided into three treatment groups: 0.01% atropine and single-vision spectacles (At+SV, n = 36), 0.01% atropine and peripheral defocus contact lens (At+PDCL, n = 30), and 0.01% atropine and dual-focus contact lens (At+DF, n = 25). A control group was prescribed single-vision spectacles (n = 36). Cycloplegic spherical equivalence refraction was measured every 6 months during 3 years of treatment and 1 year after cessation.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>\n              Myopia progression decreased over 3 years of treatment, more during the second and third years than the first year, to a statistically significant degree in the atropine groups (\n              <jats:italic>P<\/jats:italic>\n              &lt; .01): in the first, second, and third years, respectively, \u22120.42 \u00b1 0.34, \u22120.19 \u00b1 0.18, \u22120.22 \u00b1 0.19 diopters (D) in the At+SV group, \u22120.26 \u00b1 0.21, \u22120.14 \u00b1 0.37, and \u22120.15 \u00b1 0.31 D in the At+PDCL group, and \u22120.22 \u00b1 0.15, \u22120.15 \u00b1 0.22, and \u22120.11 \u00b1 0.14 D in the At+DF group. Myopia progressed 1 year after cessation of treatment: \u22120.29 \u00b1 0.28 D in the At+SV group, \u22120.13 \u00b1 0.28 D in the At+PDCL group, and \u22120.09 \u00b1 0.18 D in the At+DF group. After 3 years, there was no statistically significant difference in myopia progression between the At+SV and At+PDCL or At+DF groups (\n              <jats:italic>P<\/jats:italic>\n              &lt; .05).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Low-dose atropine has been substantiated in this cohort as an effective treatment to decelerate myopia progression over 3 years, more effective in the second and third years of treatment. The combination treatment did not exhibit a statistically significant advantage over monotherapy in this cohort. The At+DF group exhibited a statistically lower rebound effect than the At+SV group.<\/jats:p>\n            <jats:p>\n              <jats:bold>\n                [\n                <jats:italic>J Pediatr Ophthalmol Strabismus<\/jats:italic>\n                . 2024;61(3):204\u2013210.]\n              <\/jats:bold>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.3928\/01913913-20231120-01","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T13:29:43Z","timestamp":1702992583000},"page":"204-210","source":"Crossref","is-referenced-by-count":4,"title":["Effective Decrease in Myopia Progression With Two Mechanisms of Management"],"prefix":"10.3928","volume":"61","author":[{"given":"Nir","family":"Erdinest","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Atar-Vardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itay","family":"Lavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"London","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Pras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yair","family":"Morad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2308","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8491-2_2"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.12.001"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.10.029"},{"key":"e_1_3_1_5_2","first-page":"201","volume-title":"Understanding Pathologic Myopia. Updates on Myopia","author":"Ohno-Matsui K","year":"2020","unstructured":"Ohno-Matsui K, Jonas JB. Understanding Pathologic Myopia. Updates on Myopia. Springer; 2020:201\u2013218."},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004916.pub3"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-13-8491-2_5"},{"key":"e_1_3_1_8_2","first-page":"289","volume-title":"Optical Interventions for Myopia Control. Updates on Myopia","author":"Tang WC","year":"2020","unstructured":"Tang WC, Leung M, Wong AC, To C-h, Lam CS. Optical Interventions for Myopia Control. Updates on Myopia. Springer; 2020:289\u2013305."},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.12809\/hkmj187513"},{"key":"e_1_3_1_10_2","first-page":"241","volume-title":"Scleral Mechanisms Underlying Ocular Growth and Myopia. Progress in Molecular Biology and Translational Science","author":"Metlapally R","year":"2015","unstructured":"Metlapally R, Wildsoet CF. Scleral Mechanisms Underlying Ocular Growth and Myopia. Progress in Molecular Biology and Translational Science. Elsevier; 2015:241\u2013248."},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1167\/17.5.3"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000677"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001044"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001378"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001106"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8913582"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-314619"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67940-4"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001281"},{"issue":"10","key":"e_1_3_1_21_2","first-page":"1657","article-title":"The diluted atropine for inhibition of myopia progression in Korean children","volume":"11","author":"Moon J-S","year":"2018","unstructured":"Moon J-S, Shin SY. The diluted atropine for inhibition of myopia progression in Korean children. Int J Ophthalmol. 2018;11(10):1657\u20131662. PMID:30364238","journal-title":"Int J Ophthalmol"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243416"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000505"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000256"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.09.020"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14050900"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2021.1878227"}],"container-title":["Journal of Pediatric Ophthalmology &amp; Strabismus"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T19:01:16Z","timestamp":1716577276000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/01913913-20231120-01"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.3928\/01913913-20231120-01"],"URL":"https:\/\/doi.org\/10.3928\/01913913-20231120-01","relation":{},"ISSN":["0191-3913","1938-2405"],"issn-type":[{"value":"0191-3913","type":"print"},{"value":"1938-2405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}